Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Englerin A is a natural guaiane-type sesquiterpene glycolate originally isolated from the East African plant *Phyllanthus engleri*. It gained significant attention due to its potent and highly selective cytotoxicity against renal cell carcinoma (RCC) cell lines in the NCI-60 screening panel, often exhibiting IC50 values in the low nanomolar range. Mechanistically, Englerin A acts as a potent agonist of the TRPC4 and TRPC5 (Transient Receptor Potential Canonical) ion channels, leading to a lethal influx of calcium and sodium into sensitive cells. Research also indicates it activates Protein Kinase C (PKC) isoforms, which subsequently inhibits the insulin/PI3K/Akt survival pathway through the inhibitory phosphorylation of Insulin Receptor Substrate 1 (IRS1). While it has shown promising anti-tumor activity in preclinical xenograft models, its development has primarily remained in the research and preclinical stages.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on englerin A.